Hematopoietic SCT for mantle cell lymphoma: is it the standard of care? - Wikidata - awgldk - TriplyDB

Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?

Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?

http://www.wikidata.org/entity/Q37728866

about

Outcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature review Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen.

P2860

Q28087748-FDD6CB2A-166C-4E3B-9822-0F1661C9FAFA Q36837797-C3EC06E7-FCBD-4886-99BB-8A582E0160C8

P2860

Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?

http://www.wikidata.org/entity/Q37728866

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 April 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?

@en

Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?

@nl

type

label

Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?

@en

Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?

@nl

prefLabel

Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?

@en

Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?

@nl

P1433

Q37728866-4F215787-4658-4378-9C35-F89408C563C5

P1476

Q37728866-8ADA52B0-A0DC-447E-B0E7-CDA465CC9436

P2093

Q37728866-5A6B4E02-2A66-471C-9B11-BF4180B5DF13

Q37728866-C34D8D62-A08D-4766-9F56-F9D0E72CB665

Q37728866-C3D75C4F-BFCF-4556-8A87-6DC5F6BB5068

Q37728866-EA96551F-5B3D-4322-9928-2F453C713813

P2860

Q37728866-0202A743-A67B-4CD6-8211-C99B6875DE8D

Q37728866-0257E6FC-A3AF-4BF1-BF5B-3AB68BDC8E02

Q37728866-07410106-CAB5-458F-BC8C-EF6451F92417

Q37728866-0C2B2A14-86ED-42FD-AF46-4973DF37775A

Q37728866-0DC15D47-5D15-45EE-8795-BB86246EBBCC

Q37728866-0FCA11C5-46E5-4907-9603-9850A801C4E4

Q37728866-105D20B7-F254-4DB0-B3F8-1C9371DFEC04

Q37728866-14452C2B-66E8-4863-8159-BC3527BA4BA5

Q37728866-1DF85311-57F3-438D-89DF-FB360633F4C7

Q37728866-1EFF0179-16D9-46D3-A93F-DC4780E0E555

P2888

Q37728866-16C79888-9FBD-49A7-B01C-9ABC1CD18E2E

P304

Q37728866-4112154B-2FF7-4280-8C23-1B6D5D8E3870

P31

Q37728866-B32D52BA-1DB4-45A1-A971-5C9D63E09FF5

P356

Q37728866-3452D9AA-68DF-4B44-BB65-CDB11045F2E3

P407

Q37728866-FE6C60D5-C250-4B8E-AE23-C2F0EB9B1405

P433

Q37728866-4DF88463-AC50-41C3-BF1D-585EE242836B

P478

Q37728866-42D5F16A-7C1F-4BF3-9DD0-B211ECD0512B

P577

Q37728866-96562121-BCBF-438C-8BFC-03DDF74360AE

P698

Q37728866-E3D16AD1-6379-47B0-A21B-CB8CA3BF251F

P356

P1433

Bone Marrow Transplantation

P1476

Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?

@en

P2093

A Ragam

http://www.w3.org/2001/XMLSchema#string

C Nabhan

http://www.w3.org/2001/XMLSchema#string

J D Bitran

http://www.w3.org/2001/XMLSchema#string

J Mehta

http://www.w3.org/2001/XMLSchema#string

P2860

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Cancer statistics, 2009

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

P2888

P304

1379-1387

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2010.77

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20383211

http://www.w3.org/2001/XMLSchema#string